The study, evaluating the efficacy of the combination of efgartigimod alfa and hyaluronidase-qvfc, is the first to ...

Combining traditional dermatopathology with PCR-based molecular testing improves diagnostic accuracy in differentiating eczema from psoriasis, particularly in ambiguous cases.

In addition to the US, high-dose nusinersen (Spinraza; Biogen) is also approved in the European Union, Japan, and Switzerland. The patients who received nusinersen exhibited a 15.1-point improvement ...

Melinda Gooderham, MD, MSc, FRCPC, discusses findings from the Latitude PsO 3001 and Latitude PsO 3002 studies evaluating zasocitinib. This content was developed independently and is not endorsed by ...

The FDA approval of daratumumab and hyaluronidase-fihj for high-risk smoldering MM shifts care beyond watchful waiting, notes Peter Voorhees, MD. AQUILA enrolled 390 high-risk patients randomized 1:1 ...

Todd Schlesinger, MD, discusses how new immunotherapies and multidisciplinary care are reshaping treatment approaches for patients with advanced skin cancers. This content was developed independently ...

This morning, experts delivered "short and sweet" updates on treatment strategies for common dermatologic conditions. This content was developed independently and is not endorsed by the American ...

Experts at the 2026 AAD Annual Meeting urged dermatologists to engage in advocacy to protect practices and patient access amid growing challenges. Klint Peebles, MD, FAAD, a dermatologist with the Mid ...

Martina Porter, MD, discusses long-term results from the phase 3 STOP-HS program evaluating povorcitinib in patients with hidradenitis suppurativa. This content was developed independently and is not ...

April Armstrong, MD, MPH, discusses findings from the TRACE study, which evaluated the real-world effectiveness of tralokinumab in patients with skin of color with AD. This content was developed ...

Topical immunotherapy remains an effective, affordable option for alopecia areata, with long-term control seen in multimodal treatment approaches. Topical immunotherapy continues to have a significant ...

Despite its relevance to prognosis and treatment response, baseline disease duration is inconsistently reported in phase 3 clinical trials for chronic spontaneous urticaria (CSU), ...